Literature DB >> 10839615

Divergent neuroendocrine differentiation in prostatic carcinoma.

P A di Sant' Agnese1.   

Abstract

A rich variety of neuroendocrine cells are present in the normal prostate gland. Prostatic carcinoma may show divergent differentiation towards a neuroendocrine phenotype in the form of neuroendocrine small cell carcinoma or carcinoid-like tumors. Much more common is focal neuroendocrine differentiation in prostatic adenocarcinoma which may be pronounced in approximately 10% of adenocarcinomas. The prognostic significance of focal neuroendocrine differentiation in prostatic carcinoma is controversial but current evidence suggests an influence on prognosis related to hormone resistant tumors and/or a role in the conversion to a hormonal resistant phenotype. Chromogranin A appears to be the best overall tissue and serum marker of neuroendocrine differentiation. Chromogranin A serum levels may be useful in the assessment of the emergence of and/or progression of hormone resistant cancer.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10839615

Source DB:  PubMed          Journal:  Semin Diagn Pathol        ISSN： 0740-2570            Impact factor:   3.464


  8 in total

1.  Prognostic factors in prostate cancer.

Authors:  R Montironi
Journal:  BMJ       Date:  2001-02-17

2.  Skip metastase on the left neck lymph nodes of the prostatic adenocarcinoma with neuroendocrine differentiation and accompanying thyroid micropapillary carcinoma.

Authors:  Levent Sagnak; Hikmet Topaloglu; Osman Gucuk; Unsal Han; Hamit Ersoy
Journal:  Pathol Oncol Res       Date:  2008-04-02       Impact factor: 3.201

3.  A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49.

Authors:  Lawrence D True; Kent Buhler; Janna Quinn; Emily Williams; Peter S Nelson; Nigel Clegg; Jill A Macoska; Thomas Norwood; Alvin Liu; William Ellis; Paul Lange; Robert Vessella
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 4.  Mixed exocrine-neuroendocrine carcinoma of the nasal cavity: clinico-pathologic and molecular study of a case and review of the literature.

Authors:  Stefano La Rosa; Daniela Furlan; Francesca Franzi; Paolo Battaglia; Milo Frattini; Elena Zanellato; Alessandro Marando; Nora Sahnane; Mario Turri-Zanoni; Paolo Castelnuovo; Carlo Capella
Journal:  Head Neck Pathol       Date:  2012-06-28

Review 5.  Mixed pituitary adenoma/craniopharyngioma: clinical, morphological, immunohistochemical and ultrastructural study of a case, review of the literature, and pathogenetic and nosological considerations.

Authors:  Giovanna Finzi; Michele Cerati; Alessandro Marando; Cesare Zoia; Fabio Ferreli; Giustino Tomei; Paolo Castelnuovo; Stefano La Rosa; Carlo Capella
Journal:  Pituitary       Date:  2014-02       Impact factor: 4.107

6.  Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast.

Authors:  Marion Lavigne; Emmanuelle Menet; Jean-Christophe Tille; Marick Lae; Laetitia Fuhrmann; Claire Bonneau; Gabrielle Deniziaut; Samia Melaabi; Charlotte C K Ng; Caterina Marchiò; Roman Rouzier; Ivan Bièche; Anne Vincent-Salomon
Journal:  Mod Pathol       Date:  2017-09-08       Impact factor: 7.842

7.  Neuroendocrine cells of prostate cancer: biologic functions and molecular mechanisms.

Authors:  Yu-Hua Huang; Ya-Qun Zhang; Jiao-Ti Huang
Journal:  Asian J Androl       Date:  2019 May-Jun       Impact factor: 3.285

8.  Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.

Authors:  M Hammad Ather; Farhat Abbas; Nuzhat Faruqui; Mohammad Israr; Shahid Pervez
Journal:  BMC Urol       Date:  2008-12-30       Impact factor: 2.264
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.